Japan Price Revision: Mixture of Cuts And Increases Amid Supply Crisis
Market Expansion Rule Stays
Japan’s annual drug reimbursement price revision for 2023 will cut approximately $2.3bn from national healthcare costs, and while several temporary price increases have been granted to cope with an ongoing supply crisis for some products, a system of one-off revisions for big sellers remains.
You may also be interested in...
Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, talks about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis in an exclusive interview. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.
Fear of Unpredictability: Industry Criticises Japan’s Frequent Pricing Rule Changes
While Japan enters annual drug price revisions with frequent regulation changes, several major corporate players in the country warn again that government policies mean that the country is at risk of “losing attractiveness.”